Iomeron (Iomeprol)

Iomeprol contains iodine atoms that have a high atomic number, which strongly attenuates X‑ray photons. When injected, the iodine‑rich solution distributes within the vascular and extracellular compartments, increasing radiodensity of blood and perfused tissues. This heightened absorption of X‑rays creates a contrast between vessels or organs and surrounding structures on radiographic images, allowing detailed assessment of anatomy and pathology.

The dose of Iomeron is determined by the prescribing physician based on the specific imaging protocol, patient weight, renal function, and the anatomical area to be examined. The healthcare professional calculates the appropriate volume and concentration to achieve optimal image quality while minimizing exposure. Dosage information is provided in the product’s prescribing information and must be individualized for each patient.

The safety of iomeprol during pregnancy or lactation has not been fully established, and it is classified as a category where benefits must outweigh potential risks. Use is generally avoided unless the diagnostic information is essential for maternal or fetal health. Breastfeeding mothers should consult their physician; if administered, the infant may be monitored, and temporary cessation of nursing can be considered based on clinical judgment.

To place an order, visit the product page for Iomeron on the GNH India website (gnhindia.com) and submit an enquiry with the required quantity and intended use. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifying trade or institutional credentials before providing a formal quotation, confirming availability, shipping terms (including cold‑chain if required), and necessary import documentation.

Iomeron (iomeprol) is a non‑ionic, low‑osmolality iodinated contrast medium, offering a favorable safety profile compared with older high‑osmolality agents. Its physicochemical properties provide high image quality with reduced incidence of discomfort and adverse reactions. Compared with other low‑osmolality agents, differences are mainly in iodine concentration, viscosity, and specific approved indications, which the prescribing clinician evaluates for each imaging study.

Iomeron should be stored at controlled room temperature, typically below 25 °C, in its original sealed container. The solution must be protected from direct sunlight and moisture. Do not freeze or shake the vial; gently invert if mixing is required. Prior to use, inspect the container for particulate matter or discoloration, and ensure the product is within its expiry date.

Iomeron is supplied as a sterile aqueous solution for injection and is administered by a qualified healthcare professional either intravenously (IV) or intra‑arterially (IA) depending on the imaging procedure. The injection is performed using a suitable catheter or IV line, with the volume and rate adjusted to the protocol. Proper aseptic technique and patient monitoring are essential throughout the administration.

The most serious adverse events linked to iodinated contrast media like Iomeron include severe allergic reactions such as anaphylaxis, contrast‑induced nephropathy leading to acute kidney injury, and significant hypotension or cardiac arrhythmias in susceptible patients. Prompt recognition and immediate medical intervention are critical. Patients with known iodine allergy, impaired renal function, or unstable cardiovascular status require careful assessment before use.

Iomeron is contraindicated in patients with a documented hypersensitivity to iomeprol or any component of the formulation, as well as in individuals with a history of severe reactions to iodinated contrast agents. Caution is advised, and alternative imaging strategies should be considered for patients with uncontrolled asthma, severe renal impairment, or active thyroid disease that could be exacerbated by iodine exposure.